💊 Thuốc A-Z 🧬 Đích tác dụng 🛠 Công cụ 📚 Hướng dẫn
Tất cả thuốc Phân loại thuốc Lĩnh vực điều trị Tác dụng phụ
Hướng dẫn Từ điển thuật ngữ Dòng thời gian
So sánh Hành trình của thuốc Các họ thuốc
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Deferiprone

CHEMBL70927 Phase 4 Đã phê duyệt Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
139.2 g/mol
LogP
0.5
Phase
4

An oral iron chelator used to treat iron overload in thalassemia patients when other chelation therapies are inadequate or not tolerated. It binds excess iron and removes it primarily through the urine. A potentially serious side effect is agranulocytosis, a dangerous drop in white blood cells, which requires regular blood count monitoring.

Khối lượng phân tử

139,1500 g/mol

LogP

0,50

TPSA

40,50 Ų

Lipinski RO5

Đạt

Lĩnh vực điều trị

Cardiovascular Disease Osteoporosis Alzheimer's Disease Parkinson's Disease Stroke Hypertension

Cơ chế tác dụng

Forms stable, water-soluble chelate complexes with specific metal ions, facilitating their excretion from the body through the kidneys. This reduces toxic metal burden in affected tissues.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Cơ chế

Forms stable, water-soluble chelate complexes with specific metal ions, facilitating their excretion from the body through the kidneys. This reduces toxic metal burden in affected tissues.

Cấu trúc 2D

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
Cc1c(O)c(=O)ccn1C

                

                

                
                

                    
InChI

                    
InChI=1S/C7H9NO2/c1-5-7(10)6(9)3-4-8(5)2/h3-4,10H,1-2H3

                

                

                

                    
                    

                        
Molecular Formula

                        
C7H9NO2

                    

                    
                    

                        
HBD / HBA

                        
1 / 3

                    

                    
                    

                        
Liên kết có thể quay

                        
0

                    

                    
                    
                    

                        
Nguyên tử nặng

                        
10

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Câu hỏi thường gặp

                

                    
                    

                        
                        

                            
An oral iron chelator used to treat iron overload in thalassemia patients when other chelation therapies are inadequate or not tolerated. It binds excess iron and removes it primarily through the urine. A potentially serious side effect is agranulocytosis, a dangerous drop in white blood cells, which requires regular blood count monitoring.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Forms stable, water-soluble chelate complexes with specific metal ions, facilitating their excretion from the body through the kidneys. This reduces toxic metal burden in affected tissues.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Deferiprone is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL70927.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 2972.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
Tuyên bố miễn trách y tế

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.